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Abstract: White matter lesions (WML) are a common feature of the ageing brain associated with
cognitive impairment. The gene expression profiles of periventricular lesions (PVL, n = 7) and
radiologically-normal-appearing (control) periventricular white matter cases (n = 11) obtained from
the Cognitive Function and Ageing Study (CFAS) neuropathology cohort were interrogated using
microarray analysis and NanoString to identify novel mechanisms potentially underlying their formation.
Histological characterisation of control white matter cases identified a subgroup (n = 4) which
contained high levels of MHC-II immunoreactive microglia, and were classified as “pre-lesional.”
Microarray analysis identified 2256 significantly differentially-expressed genes (p ≤ 0.05, FC ≥ 1.2)
in PVL compared to non-lesional control white matter (1378 upregulated and 878 downregulated);
2649 significantly differentially-expressed genes in “pre-lesional” cases compared to PVL (1390 upregulated
and 1259 downregulated); and 2398 significantly differentially-expressed genes in “pre-lesional” versus
non-lesional control cases (1527 upregulated and 871 downregulated). Whilst histological evaluation of
a single marker (MHC-II) implicates immune-activated microglia in lesion pathology, transcriptomic
analysis indicates significant downregulation of a number of activated microglial markers and suggests
established PVL are part of a continuous spectrum of white matter injury. The gene expression profile of
“pre-lesional” periventricular white matter suggests upregulation of several signalling pathways may be
a neuroprotective response to prevent the pathogenesis of PVL.
Keywords: periventricular lesions; transcriptomic profiling; nanostring; immune response
1. Introduction
Age-associated white matter lesions (WML) appear as hyperintensities on T2-weighted magnetic
resonance images (MRI) and are frequently observed in people aged over 65 years [1]. These WML are
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often interpreted as a surrogate for small vessel disease and are associated with an increased risk of
dementia [2–4]; the impact of WML on cognition is related to their neuroanatomical locations [5].
WML can be subclassified as periventricular (PVL) or deep subcortical lesions (DSCL), which both
share similar histopathological features, including myelin attenuation, axonal damage, astrogliosis and
microglial activation, as reviewed in [6–8]. However, differences in the cellular pathology profiles of these
WML have also been reported, particularly in relation to their microglial phenotype. Microglia share
functions with tissue macrophages, including surveillance, antigen presentation and phagocytosis [9].
Previous studies suggest microglia within PVL have a predominantly pro-inflammatory immune reactive
phenotype, associated with the expression of the major histocompatibility complex class II (MHC-II) and
co-stimulatory molecule B7-2 (CD80) [10], while microglia within DSCL have a phagocytic phenotype
associated with the abundance of CD68+ amoeboid microglia [11,12].
The exact mechanism(s) underlying the pathogenesis of WML remains unknown. However chronic
cerebral hypoperfusion [13,14], dysfunction of the blood brain-barrier (BBB) [15–17] and cortical pathologies
have been linked to their formation [18]. WML show arteriolar thickening, perivascular widening,
capillary loss and perivenous collagenosis, with DSCL in particular associated with the expression of high
levels of a number of hypoxia response molecules, suggesting that vascular insufficiency and consequent
hypoperfusion underlie their formation [13]. This is further supported by transcriptomic profiling of DSCL,
which has confirmed increased expression of hypoxia-related genes, and also identified dysregulation of
immune-regulatory genes, including those involved with antigen presentation, pro-inflammatory cytokine
signalling and phagocytosis [19].
Transcriptomic analyses enable the identification of relevant gene expression changes that are often
missed in targeted approaches. While histological studies suggest BBB dysfunction, serum protein
accumulation and microglial activation underlie the pathogenesis of PVL [10,15,20], to date no studies have
employed transcriptomic analysis to characterise their profile. Therefore, the current study interrogated
the gene expression profile of PVL using two independent approaches to identify novel mechanisms
potentially underlying their formation.
2. Results
2.1. Histological Characterisation of Periventricular White Matter
MRI of the formalin-fixed hemisphere was used to guide sampling of the contralateral frozen
periventricular white matter, and histological characterisation of the sampled frozen blocks was performed
to confirm the tissue status as non-lesional control periventricular white matter or PVL. These frozen blocks
were then sampled for transcriptomic analysis. All non-lesional control cases displayed preservation of
myelin throughout the periventricular region and an intact ependymal lining (Figure 1A,B,D,E). In contrast,
all PVL cases were characterised by a reduction in luxol fast blue (LFB) staining, indicative of myelin
attenuation (Figure 1C), and partial denudation of the ependyma in four out of seven of the cases (Figure 1F).
To further characterise the periventricular white matter samples, activated microglia were visualised
using MHC-II, which immunolabelled the microglial cell body and proximal processes. Seven cases of
radiologically and histologically-rated non-lesional control white matter contained low levels of MHC-II
immunoreactive microglia throughout the periventricular region (Figure 1G); however, four cases contained
high levels of MHC-II expression (Figure 1H). While the MRI and histological characterisation had indicated
that there was no demyelination, the immunoreactive profile of MHC-II suggested microglial activation;
therefore, the non-lesional group was subsequently subdivided into non-lesional control (no demyelination;
low levels of MHC-II immunoreactivity, n = 7) and “pre-lesional” cases (no demyelination; high levels of
MHC-II+ microglia, n = 4). Seven cases of radiologically and histologically-identified PVL contained high
levels of MHC-II+ microglia (Figure 1I).
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Figure 1. Histological characterisation of periventricular white matter. Luxol fast blue (LFB) (A,B) and
H&E staining (D,E) of radiologically normal appearing white matter demonstrated a regular pattern of
myelin staining across the periventricular region. In contrast, LFB (C) and H&E staining (F) of radiologically
identified lesional cases displayed a band of periventricular demyelination. MHC-II immunostaining
of radiologically normal appearing white matter identified cases with minimal MHC-II+ microglia ((G),
control) but also cases with high levels of MHC-II immunoreactivity ((H), “pre-lesional”). Radiologically
identified periventricular lesions (PVL) contained high levels of MHC-II+ microglia (I). Scale bar represents
500 µm in (A–F) and 100 µm in (G–I).
2.2. Microarray Analysis
Based on the bioanalyser RNA quality profile, transcriptomic analysis of 18 periventricular white
matter cases (seven control, four “pre-lesional” and seven PVL) was performed using Human Genome
U133 Plus 2.0 Arrays, which contain at least one probe for each gene and recognize over 39,000 genes.
Principal component analysis (PCA) showed clear separation of the three groups and confirmed there were
no sample outliers (Figure 2); quality control (QC) measures were within an acceptable range. After setting
the stringency parameters to fold change≥ 1.2 and p value≤ 0.05, 2256 genes were significantly differentially
expressed in PVL compared to non-lesional control (1378 upregulated and 878 downregulated); 2649 were
significantly differentially-expressed genes in “pre-lesional” cases compared to PVL (1390 upregulated and
1259 downregulated); and 2398 genes were significantly differentially expressed in “pre-lesional” versus
non-lesional control cases (1527 upregulated and 871 downregulated). The microarray datasets are freely
available at the Gene Expression Omnibus (GEO) public database (accession code GSE157363).
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Figure 2. Principle component analysis (PCA) of ageing periventricular transcriptomic datasets. The PCA
plot of control (blue), “pre-lesion” (yellow) and PVL (pink) shows a separation of differentially-expressed
genes between the groups.
In PVL compared to non-lesional control periventricular white matter, functional grouping analysis
with the highest stringency settings identified enrichment of genes that were associated with MHC
antigen processing and presentation, major histocompatibility II receptor activity and collagen IV.
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis in the Database for Annotation,
Visualization and Integrated Discovery (DAVID) identified 53 significantly dysregulated pathways
(Supplementary Materials, Table S1), including immune response-associated pathways (Table 1). In PVL,
genes associated with antigen processing and presentation (MHC-II) were significantly downregulated,
including HLA-DRA (probeset 210982_s_at, FC = −1.71, p = 0.0038) and CD74 (probeset 1567627_at,
FC = −2.67, p = 0.0068). Significant downregulation of genes associated with the phagosome was also
detected, including FCGR1A (probeset 216951_at, FC = −2.12, p = 0.0164).
Table 1. KEGG pathway analysis of PVL versus control white matter transcriptomic datasets.
Pathway Count p-Value
hsa04612: Antigen processing and presentation 20 9.17 × 10−6
hsa04145: Phagosome 24 0.003
hsa04672: Intestinal immune network for IgA production 11 0.004
hsa04662: B cell receptor signalling pathway 12 0.026
In “pre-lesional” compared to non-lesional control periventricular white matter, functional grouping
analysis revealed enrichment of genes associated with calcium signalling, glutamate receptor activity,
GABA receptor activity and MHC classes I/II-like antigen recognition protein. KEGG pathway analysis
identified 79 significantly dysregulated pathways (Supplementary Materials, Table S2), including immune
response-associated signalling pathways (including calcium, cAMP and MAPK) and synaptic pathways
(including glutamatergic, dopaminergic and cholinergic synapses) (Table 2). In “pre-lesional” cases,
multiple genes associated with the phagosome, antigen processing and antigen presentation were
downregulated, including HLA-DPA1 (probeset 213537_at, FC=−2.72, p= 0.0004) and HLA-DQB1 (probeset
211654_x_at, FC = −1.76, p = 0.0046). Upregulation of multiple genes associated with calcium signalling
and synaptic signalling was found, including calcium voltage-gated channel subunit alpha 1E (CACNA1EI)
(probeset 236013_at, FC = 4.46, p = 0.001; probeset 244256_at, FC = 4.11, p = 0.001; probeset 240650_at,
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FC = 1.31, p = 0.016; probeset 208432_s_at, FC = 1.62, p = 0.012) and calcium/calmodulin-dependent
protein kinase IV (CAMK4) (probeset 229029_at, FC = 2.74, p = 0.0008; probeset 241871_at, FC = 3.31,
p = 0.0008), along with upregulation of genes associated with GABAergic synaptic signalling, including
gamma-aminobutyric acid (GABA) A receptor alpha 5 GABRA5 (probeset 206456_at, FC = 7.1, p = 0.0002;
probeset 215531_s_at, FC = 3.89, p = 0.001; probeset 217280_x_at, FC= 1.6, p = 0.009).
Table 2. KEGG pathway analysis of “pre-lesional” versus control white matter transcriptomic datasets.
Pathway Count p-Value
hsa04020:Calcium signalling pathway 42 3.38 × 10−9
hsa04728:Dopaminergic synapse 34 5.29 ×10−9
hsa04724:Glutamatergic synapse 30 6.28 × 10−8
hsa04725:Cholinergic synapse 29 1.29 × 10−7
hsa04727:GABAergic synapse 23 1.82 × 10−6
hsa04612:Antigen processing and presentation 20 1.58 × 10−5
hsa04024:cAMP signalling pathway 34 1.54 × 10−4
hsa04010:MAPK signalling pathway 40 2.23 × 10−4
hsa04145:Phagosome 25 0.002
hsa04062:Chemokine signalling pathway 28 0.005
hsa04151:PI3K-Akt signalling pathway 45 0.005
hsa04660:T cell receptor signalling pathway 17 0.011
hsa04662:B cell receptor signalling pathway 13 0.014
hsa04068:FoxO signalling pathway 19 0.038
In “pre-lesional” periventricular white matter compared to PVL, functional grouping analysis identified
an enrichment of genes associated with GABA receptor activity, adenylate cyclase activity, metallothionein
and neurotransmitter gated ion channels. KEGG pathway analysis identified 38 significantly dysregulated
pathways (Supplementary Materials, Table S3), including signalling pathways (including calcium, cAMP,
cGMP and MAPK) and synaptic pathways (including glutamatergic, GABAergic and dopaminergic
synapses) (Table 3). Significant upregulation of multiple genes encoding the calcium signalling
pathway was detected in “pre-lesional” periventricular white matter, including upregulation of
calmodulin 1 and calmodulin 2 (CALM1 and CALM2) (probeset 213688_at, FC = 1.59, p = 0.016) and
calcium/calmodulin-dependent protein kinase II alpha (CAMK2A) (probeset 213108_at, FC = 1.67, p = 0.043;
probeset 207613_s_at, FC = 7.06, p = 0.008); and upregulation of genes associated with glutamatergic
signalling, including glutamate receptor, ionotropic, N-methyl D-aspartate 1 (GRIN1) (probeset 205915_x_at,
FC = 1.45, p = 0.011; probeset 211125_x_at, FC = 1.65, p = 0.041; probeset 210781_x_at, FC = 1.82, p = 0.018),
glutamate receptor, ionotropic, AMPA 2 (GRIA2) (probeset 241172_at, FC = 1.55, p = 0.015) and GRIA3
(probeset 1569290_s_at, FC = 1.6, p = 0.017; probeset 217565_at, FC = 1.87, p = 0.021; probeset 208032_s_at,
FC = 2.38, p = 0.0005; probeset 230144_at, FC = 2.66, p = 0.004; probeset 206730_at, FC = 2.94, p = 0.006).
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Table 3. KEGG pathway analysis of “pre-lesional” versus PVL transcriptomic datasets.
Pathway Count p-Value
hsa04020:Calcium signalling pathway 46 4.71 × 10−11
hsa04724:Glutamatergic synapse 29 3.97 ×10−7
hsa04727:GABAergic synapse 21 3.58 × 10−5
hsa04725:Cholinergic synapse 23 2.30 × 10−4
hsa04310:Wnt signalling pathway 26 3.83 × 10−4
hsa04024:cAMP signalling pathway 33 5.36 × 10−4
hsa04022:cGMP-PKG signalling pathway 28 5.96 × 10−4
hsa04728:Dopaminergic synapse 22 0.0039
hsa04010:MAPK signalling pathway 34 0.0143
2.3. EnrichR
The top 1000 significantly differentially-expressed genes in the PVL versus control non-lesional
white matter dataset were imported into EnrichR to check their relationships with KEGG pathways,
biological processes, panther pathways and the human gene atlas. The top pathway or functional group
identified in each analysis included: antigen processing and presentation (KEGG pathway p = 6.77 × 10−6);
inflammation (panther pathway, p = 0.0001); and MHC-II (cellular component p = 0.0001). The top 10
pathways/functional groups identified by EnrichR are shown in Table 4.
Table 4. Enrich R analysis of PVL versus control non-lesional white matter transcriptomic datasets. The top
10 pathways/functional groups identified by the analysis are shown below.
Pathway/Functional Group p-Value
KEGG pathway
hsa04612: Antigen processing and presentation 6.77 × 10−6
hsa05169: Epstein-Barr virus infection 1.06 × 10−4
hsa05215: Prostate cancer 1.49 × 10−4
hsa05140: Leishmaniasis 4.58 × 10−4
hsa05168: Herpes simplex infection 8.04 × 10−4
hsa05332: Graft-versus-host disease 8.61 × 10−4
hsa04940: Type I diabetes mellitus 0.0012
hsa04915: Estrogen signalling pathway 0.0015
hsa05330: Allograft rejection 0.003
hsa05164: Influenza A 0.0031
Panther pathway
P00031: Inflammation mediated by chemokine and cytokine signalling 1.20 × 10−4
P00053: T cell activation 0.0068
P02756: N-acetylglucosamine metabolism 0.0199
P02776: Serine glycine biosynthesis 0.0199
P00010: B cell activation 0.0217
P00007: Axon guidance mediated by semaphorins 0.0257
P00049: Parkinson disease 0.0359
P00054: Toll receptor signalling pathway 0.0391
P00006: Apoptosis signalling pathway 0.0426
P04386: Histamine H2 receptor mediated signalling pathway 0.0443
Gene Ontology (cellular component)
GO:0042613: MHC class II protein complex 1.24 × 10−4
GO:0016607: nuclear speck 3.02 × 10−4
GO:0045121: membrane raft 4.73 × 10−4
GO:0012507: ER to Golgi transport vesicle membrane 5.67 × 10−4
GO:0030671: clathrin-coated phagocytic vesicle membrane 9.54 × 10−4
GO:0016606: LYSP100-associated nuclear domain 0.0022
GO:0010445: nuclear dicing body 0.0022
GO:0071601: sphere organelle 0.0022
GO:0016604: nuclear body 0.0022
GO:0035363: histone locus body 0.0023
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2.4. Computational Deconvolution of Microglial Gene Expression
To focus the results on changes in the microglial phenotype, bone marrow stromal cell antigen 2 (BST2),
also referred to as CD317 or tetherin, was used to identify the co-expressed genes associated with inactivated
microglia (group A), while for activated microglia, TREM2, HLA-DRA, ENTPD1, CD80, CD86, CCR5,
CD274, ITGAX, TIMD4 and MRC1 were selected (group B). In both activated and inactivated microglia
groups, 17 genes were co-expressed with the gene set selected (Table 5), which showed similar patterns of
expression in the three groups: non-lesional control, “pre-lesion” and PVL (Figure 3). Overall analysis of
the co-expressed genes suggested similar levels of activated and inactivated microglia within PVL and
“pre-lesions” compared to non-lesional control white matter, with the exception of CD80 which showed a
marked decrease in expression in PVL (Figure 3).
Table 5. Microglial deconvolution. BST2 (CD317) was used to identify the co-expressed genes associated
with inactivated microglia (group A), while for activated microglia TREM2, HLA-DRA, ENTPD1, CD80,
CD86, CCR5, CD274, ITGAX, TIMD4 and MRC1 were selected (group B).
Group A (Inactivated Microglia) Group B (Activated Microglia)
ISG15 HLA-DPB1
MX1 HLA-DQB1
IFI44L HLA-DMB
OAS2 HLA-DPA1
IFI35 LCP2
OAS1 FCER1G
LY6E GBP5
IFIT1 CYBB
IFI44 SAMSN1
UBE2L6 SLAMF8
IFIT3 MS4A6A
IRF7 IGSF6
XAF1 HAVCR2
RSAD2 TFEC
OAS3 CD163
IRF9 FCGR2A
USP18 MSR1
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Figure 3. Graphical representation of gene annotations in activated and inactivated microglia in ageing
periventricular white matter. BST2 was used to identify the co-expressed genes associated with inactivated
microglia (A–A3). For activated microglia, TREM2, HLA-DRA, ENTPD1, CD80, CD86, CCR5, CD274,
ITGAX, TIMD4 and MRC1 were selected (B–B3). C: non-lesional control white matter; P: “pre-lesional”;
L: periventricular lesion.
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2.5. Validation of Candidate Gene Expression by NanoString nCounter
Nanostring is a hybridisation-multiplex digital technology which uses capture probes and unique
color-coded barcode reporter probes to measure a broad range of mRNA in a single reaction without the
need of reverse transcription of mRNA or amplification of cDNA.
NanoString data analysis was employed to validate a panel of candidate gene expression changes
identified in the microarray analysis of PVL versus non-lesional control white matter. NanoString analysis
confirmed the significant differential expression of seven genes (CCL3 p = 0.008; CCR5 p = 0.0002;
CD74 p = 0.013; CX3CR1 p = 0.01; IL1B p = 0.0007; JUN p = 0.008; PTGS2 p = 0.007), and identified 19 genes
which showed the same directional changes to the microarray findings, although not reaching statistical
significance (Table 6).
Table 6. Validation of candidate gene expression by NanoString nCounter.
Microarray NanoString
Gene Fold Change p-Value Fold Change p-Value
AKT3 1.33 0.002 ** 1.52 0.127
CCL2 −1.7 0.05 * −1.88 0.290
CCL3 −1.31 0.05 * −16.11 0.008 **
CCL4 −1.16 0.060 −5.14 0.098
CCR5 −1.49 0.01 * −2.17 0.0003 ***
CD163 −3.27 0.315 −1.07 0.928
CD74 −2.67 0.006 ** −1.54 0.013 *
CD8A −1.28 0.016 * −1.23 0.567
COL6A3 −1.62 0.01 * −1.72 0.074
CX3CR1 −1.5 0.005 ** −1.64 0.01 *
CYBB −1.62 0.013 * −1.17 0.577
EPSTI1 −1.31 0.839 −1.39 0.101
FCER1G −1.52 0.076 −1.28 0.265
FGL2 −1.77 0.012 * −1.29 0.190
FPR1 −2.39 0.017 * −2.82 0.066
HLA-DRA −1.71 0.004 ** −1.51 0.071
IFNAR1 1.79 0.004 ** 1.25 0.190
IGSF6 −1.27 0.257 −1.12 0.585
IKBKB 1.38 0.839 1.88 0.097
IL1A −1.06 0.206 −1.71 0.061
IL1B −1.34 0.01 * −4.72 0.007 **
IRF7 1.04 0.673 −1.04 0.846
JUN 1.33 0.008 ** 1.98 0.008 **
MSR1 −1.95 0.023 * −1.06 0.877
OAS1 −1.12 0.83 1.14 0.644
PHF21A 1.36 0.008 ** 1.5 0.121
PTGS2 −1.3 0.011 * −2.59 0.007 **
RSAD2 −1.2 0.065 1.09 0.757
SLAMF8 −1.03 0.679 −1.48 0.327
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, down-regulated transcripts (pink), up-regulated transcripts (green).
2.6. Validation of Candidate Gene Expression by Immunohistochemistry
To further validate our transcriptomic findings, we selected a panel of four biologically relevant
genes from pathways highlighted by both the microarray and NanoString datasets (CD74, IL1B, CD163,
CD86). Expression of proteins encoded by the genes of interest were examined by immunohistochemistry
(Figure 4), and the immunoreactive area of CD74, IL-1β, CD163 and CD86 staining in the periventricular
white matter was quantified within each group (Table 7). CD74 immunolabelled microglia with a ramified
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morphology and were mainly present in the non-lesional control group (Figure 4A–C). Expression of CD74
significantly differed across the three groups (p = 0.002), with non-lesional control periventricular white
matter containing significantly higher levels of CD74 immunoreactivity compared to both “pre-lesional”
(p = 0.033) and PVL (p = 0.003) (Figure 5A). IL-1β, CD163 and CD86 immunoreactivity was predominantly
associated with the cell bodies and extending processes of cells morphologically resembling microglia.
Expression of IL-1β (p = 0.7), CD163 (p = 0.38) and CD86 (p = 0.63) immunoreactivity did not significantly
vary across the three groups (Figure 5B–D).
 
 
Ά
Figure 4. Histological validation candidate gene expression changes. Expression of proteins encoded by
candidate genes highlighted by both microarray and NanoString datasets was assessed. (A–C) CD74,
(D–F) IL-1β, (G–I) CD163 and (J–L) CD86 immunolabelled cell bodies and processes of microglia in all
periventricular white matter groups: non-lesional control white matter (A,D,G,J); “pre-lesional” white
matter (B,E,H,K); and PVL (C,F,I,L). Scale bar represents 100 µm.
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Table 7. Expression of CD74, IL-1β, CD163 and CD86 in ageing periventricular white matter. The percentage
area of immunoreactivity of each of the markers is shown, median (IQR).
WM Group Control Pre-Lesional PVL
CD74 3.47 (3.08–4.15) 1.66 (0.9–2.14) 1.3 (1.13–1.66)
IL-1β 3.87 (1.91–4.86) 2.76 (1.91–4.07) 3.43 (2.48–4.22)
CD163 0.93 (0.75–1.21) 0.39 (0.29–1.08) 0.95 (0.59–1.32)
CD86 4.55 (4.52–5.66) 5.34 (3.98–6.23) 5.04 (3.35–6.03)
IQR: inter-quartile range.
 
 
Ά
Figure 5. Quantitation of the expression of candidates in periventricular ageing white matter. The percentage
area immunoreactivity of the protein encoded by a panel of candidate genes was assessed in the three
periventricular white matter groups. (A) CD74 expression was significantly higher in non-lesional
control periventricular white matter compared to both “pre-lesional” (p = 0.033) and PVL (p = 0.003).
The immunoreactive profiles of (B) IL-1β, (C) CD163 and (D) CD86 did not significantly differ across the
three groups. * p < 0.05, *** p < 0.005.
3. Discussion
Age-associated WML correlate with reductions in information processing speed and executive function,
and are associated with an increased risk of developing dementia [8,21]. Histological characterisation and
transcriptomic profiling of DSCL suggest that vascular insufficiency and hypoperfusion underlie their
formation [13], but to date no comparable studies have interrogated the gene expression profile of PVL.
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The current study employed two independent approaches to characterise the transcriptomic signature
of PVL, aiming to identify potential mechanisms underlying their pathogenesis. We demonstrate that
established, demyelinated PVL are associated with dysregulation of the immune response, whilst increased
signalling is a feature of “pre-lesional” periventricular white matter and may represent attempts to prevent
lesion formation.
PVL are characterised by dysfunction of the BBB and significant levels of immune-activated MHC-II+
microglia [10,15,17], suggesting that a loss of cerebrovascular integrity and the resulting microglial activation
contribute to lesion pathology. In the current study, radiologically identified PVL and non-lesional control
periventricular white matter cases underwent histological validation, including assessment of MHC-II
immunoreactivity, prior to transcriptomic profiling. As expected, demyelination and MHC-II+ microglia
are prominent features of PVL; however, a subgroup of radiologically normal periventricular white matter
cases were identified, which showed no evidence of demyelination but contained moderately high levels of
MHC-II+microglia. The transcriptomic profile of these cases was subsequently assessed independently and
termed “pre-lesional,” although it should be acknowledged that it cannot be definitively known whether
these cases would have progressed to develop clinically relevant PVL. Extensive detailed histological
characterisation studies are required to fully elucidate the profile of these “pre-lesions”.
Microarray analysis indicates that the transcriptome of “pre-lesional” cases is distinct from
radiologically and histologically control-grade white matter from non-lesional cases, and similarly
to PVL, is associated with the dysregulation of immune function-associated genes. In contrast to
increased immunohistochemical detection of MHC-II, several HLA-associated transcripts are significantly
down-regulated in both “pre-lesion” and PVL compared to non-lesional control white matter.
It should, however, be noted that mRNA and protein expression can be decoupled in time [22,23],
and that transcriptomic profiling of post-mortem tissue indicates the gene expression profile at one
timepoint. While this discordant result appears to argue against the use of transcriptomic profiling
technologies to identify potential biologically relevant gene expression changes, it has been shown that
differentially-expressed transcripts have significantly higher correlations between mRNA and protein
levels when compared to transcripts that are not differentially expressed [23], giving confidence for the
use of mRNA profiling in the current study. Indeed CD74—a protein that associates with MHC-II and is
an important chaperone that regulates antigen presentation for the immune response—is significantly
down-regulated in “pre-lesional” cases and PVL, at both the mRNA and protein levels.
As gene expression profiling was conducted on total tissue extracts, which may have masked
cell-specific changes in the transcriptome, we performed a computational deconvolution to interrogate
changes in gene expression specific to microglial phenotypes within “pre-lesions” and PVL. BST2 (CD317)
is associated with inactivated microglia [24] and diminishes the expression of inflammatory genes [25];
therefore, BST2 was selected to identify the co-expressed genes associated with inactivated microglia.
The phenotypic transformation from homeostatic microglia towards reactive microglia in dementia
pathologies is associated with TREM2 [26], HLA-DRA [27], ENTPD1 (CD39) [28], CD80 (B7-1) [29],
CD86 (B7-2) [10], CCR5 [30], CD274 [31], ITGAX (CD11c) [32], TIMD4 [33] and MRC1 [34]. Therefore,
these candidates were used in the deconvolution analysis to identify co-expressed genes associated with
active microglia in “pre-lesions” and PVL. Overall, our data are consistent with similar levels of both
active and inactive-associated microglial transcripts being present in both “pre-lesions” and PVL, with the
exception of CD80 (expressed by antigen presenting cells), which showed a marked decrease in expression
in PVL. Overall, our data demonstrate a heterogenous microglial population within periventricular white
matter, highlighting the microglial diversity in the periventricular regions of the ageing brain and the need
to examine an extensive panel of markers when assessing the microglial phenotype.
Expression of a panel of candidate gene expression changes identified in the microarray analysis
of PVL compared to control white matter was validated using NanoString. This novel, robust profiling
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technology has the ability to analyse low RNA quality and enables the quantification of mRNA without
the use of reverse transcription or amplification of cDNA [35], which is advantageous when assessing
post-mortem material. In PVL compared to the non-lesional control group, 65% of the genes assessed
displayed a non-significant but similar directional change between both platforms, and 24% of the genes
revealed a significant difference with similar directional change, validating the findings of the array
analysis. Among the validated gene expression changes, significant down-regulation of the chemokine
receptors CCR5 and CX3CR1, the chemokine CCL3 and pro-inflammatory cytokine IL1B are features of
established PVL. Expressions of these chemoattractant cytokines and receptors are a prominent feature
of active multiple sclerosis lesions and their animal models, where they are primarily associated with
active microglia and ongoing demyelination [36–38]; in contrast, their levels significantly decrease in
established PVL.
Cerebral white matter supports the bidirectional transfer of signals between the cortex and subcortical
structures, where dysregulation of signalling impacts communication and cognitive function [21].
Comparison of the transcriptomic profile of “pre-lesional” white matter with both control white matter and
PVL indicates significant upregulation of signalling and synaptic pathways. Loss of white matter integrity
following ischaemic stroke in aged mice is mainly attributed to Ca2+ dyshomeostasis, which ultimately
induces oligodendrocyte loss and axonal disruption [39]; therefore, the significant increase in calcium
signalling in “pre-lesional” white matter may represent a potential neuroprotective mechanism to
prevent lesion formation. Axons release vesicles containing glutamate during the propagation of action
potentials [40]. Glutamate receptors are expressed by mature oligodendrocytes [41], and communication
between axons and myelin has led to the axon–myelin–synapse hypothesis [42], wherein glutamate
signalling is a mechanism whereby adaptive myelination occurs in electrically active axons. The current
study demonstrates an increase in synaptic signalling is a feature of “pre-lesions” which may reflect a
mechanism to maintain myelin integrity and prevent lesion pathogenesis.
The current study performed transcriptomic profiling of a small number of cases (seven non-lesional
control, four “pre-lesional” and seven PVL); however, it should be acknowledged that interrogation
of 12 or more cases per group may be required to detect all of the significant differentially-expressed
genes [43]. Therefore, as some gene expression changes may not have been detected, future research
on a larger cohort of cases is required. A further limitation of the current study is the interpretation
of the transcriptomic datasets with a bias towards assessing the microglial phenotype associated with
ageing periventricular white matter pathology. The total periventricular region isolated by LCM will have
contained a heterogeneous population of cells. While several of the candidate gene expression changes are
associated with microglial functions and phenotypes, including HLA-associated transcripts, they are not
uniquely associated with microglia and may reflect changes in the transcriptomic profiles of other cells,
for example, astrocytes. Future research is required to confirm which cell population(s) are associated with
the candidate genes identified in study.
Age-associated PVL are significantly associated with cognitive decline in the ageing population,
but very little is known about the mechanisms underlying the pathology of these lesions. Overall,
our data suggest that established PVL are part of a continuous spectrum of white matter injury, and that
increased signalling in “pre-lesional” white matter may be a neuroprotective mechanism to prevent the
pathogenesis of PVL. Future studies focussing on these pathways is required, as they may represent a
potential therapeutic target to prevent lesion formation.
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4. Materials and Methods
4.1. Human CNS Tissue
Frozen human post-mortem CNS tissue was obtained from the CFAS neuropathology cohort,
following multi-centre Research Ethical Committee (REC) approval (REC Reference number 15/SW/0246,
approved on 10th August 2015). While this cohort is representative of the ageing population, the current
study was conducted with a case-control design, as previously described [7]. MRI of formalin fixed
post-mortem coronal brain slices was used to guide case selection and sampling of the contralateral
frozen hemisphere, using our previously published protocol [19]. A modified Schelten’s semi-quantitative
rating [44], was used to select 7 PVL and 11 radiologically-normal-appearing control periventricular white
matter cases (Table 8). All radiologically normal control samples scored 0 in both periventricular and deep
subcortical regions. All PVL samples scored 3 in the periventricular MRI rating; three samples scored 0 in
the deep subcortical region, three samples scored 3 and one sample scored 5.
Table 8. Cohort demographics.
Experimental Approach Classification Median Age (y) (Range) Gender (M/F) PMD (h) (Range)
Microarray Control (n = 11) 84 (70–89) 4/7 11 (6–42)
PVL (n = 7) 89 (85–95) 3/4 28 (7–72)
NanoString Control (n = 7) 84 (70–89) 2/5 14 (6–42)
PVL (n = 5) 88 (85–95) 2/3 28 (18–72)
4.2. Histological Characterisation
Frozen sections (10 µm) were fixed in ice-cold acetone at 4 ◦C for 10 min and stained with haematoxylin
and eosin (H&E) or luxol fast blue (LFB) to confirm the presence of PVL or non-lesional periventricular white
matter. Previous studies have shown that PVL contain significantly high levels of MHC-II+ microglia [10];
therefore, immunohistochemistry (IHC) was performed to detect this marker of microglial activation using
a standard Avidin–biotin complex-horse radish peroxidase (ABC-HRP) approach. Antibody conditions
and suppliers are shown in Table 9.
Table 9. Antibody sources and conditions.
Antibody Isotype Dilution (Time, Temperature) Supplier
CD163 Monoclonal Mouse IgG 1:100 (1 h RT) Bio-Rad, UK
CD68 (PG-M1) Mouse, IgG3κ 1:100 (1 h RT) Dako, UK
CD74 Polyclonal Rabbit IgG 1:200 (1 h RT) Sigma, UK
CD80/B7-1 Monoclonal Mouse IgG1 1:20 (overnight 4
◦C) R&D Systems, UK
CD86/B7-2 Polyclonal goat IgG 1:20 (overnight 4 ◦C) R&D Systems, UK
CX3CR1 Monoclonal Mouse IgG1 1:25 (overnight 4
◦C) Biolegend, UK
IL-1β Polyclonal Rabbit IgG 1:200 (1 h RT) Proteintech, UK
MHC-II (HLA-DR) Mouse Monoclonal IgG 1:20 (1 h RT) Dako, UK
Key: h: hour; RT: room temperature; IL-1β: interleukin 1 beta; κ: Kappa.
4.3. Laser Capture Microdissection (LCM)
Cryosections (10 µm) were fixed in ice-cold acetone for 3 min before staining with Toluidine blue and
rinsing with diethylpyrocarbonate (DEPC)-treated water, for 30 s each. Sections were dehydrated in a
graded series of ethanol (70%, 95%, 100% for 15 s each), cleared in xylene and left to air dry in an air flow
hood for at least 60 min before LCM. The periventricular region of interest was isolated using a PixCell II
laser-capture microdissection system (Arcturus BioScience, Mountain View, CA, USA), and CapSure macro
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caps (Arcturus Engineering, Mountain View, CA, USA). Briefly, LCM of the periventricular white matter
was performed using 30 µm laser spot size and a pulse power of 65–90 mW. Following microdissection,
RNA was extracted using the PicoPure RNA extraction kit, according to manufacturer’s protocol (Arcturus
BioScience, Mountain View, CA, USA). Pre- and post-LCM RNA quality was assessed using a Bioanalyser
(Agilent, CA, USA).
4.4. Microarray
RNA was prepared according to the GeneChip 3′ IVT express amplification protocol (Affymetrix,
Stockport, UK). RNA was reverse transcribed to produce single-stranded cDNA by annealing the total
RNA with an oligo-d(T) primer with a T7 polymerase binding site. The cDNA was converted into
double-stranded cDNA by DNA polymerase and RNAse H. Biotin-labelled cRNA was made using
an in vitro transcription (IVT) labelling kit. Following clean-up and purification of the biotin labelled
cRNA, samples were checked using the bioanalyzer to ensure sufficient RNA had been generated (Agilent
Bioanalyzer 2100). Samples (12µg) were analysed using GeneChip Human U133 Plus 2.0 arrays (Affymetrix,
Stockport, UK).
4.5. Transcriptomic Analysis of Microarrays
Quality control (QC) analysis was performed to confirm amplification, hybridisation, expression of
housekeeping genes and signal intensity using Affymetrix Expression Console software (Affymetrix®,
Stickport, UK). Transcriptome Analysis Console (TAC) software version 4.1.1 (Affymetrix®, Stockport,
UK) was used to analyse and compare the gene expression profile of the 3 groups. Genes were considered
significantly differentially expressed if they showed a minimum fold change (FC) ≥ +/−1.2 and p ≤ 0.05.
Qlucore Omics Explorer (Qlucore, Lund, Sweden) was used to identify the distribution of the samples using
principal component analysis (PCA). The significantly differentially-expressed genes were analysed using
the Database for Annotation Visualisation and Integrated Discovery (DAVID) annotation website version
6.8, identifying the key gene expression changes in both pathways and functional groups. Annotated genes
were filtered using the highest stringency settings to obtain high specificity and minimizing the rate of
false-positives. Subsequent analysis focussed on the top 1000 differentially-expressed genes from each
comparison group, and they were analysed using EnrichR, an online tool which aids clustering of the
genes based on their similar functions. Affymetrix probe IDs were converted into Entrez Gene IDs using
Database for Annotation, Visualisation and Integrated Discovery (DAVID) version 6.8 Gene ID conversion
tool (david.ncifcrf.gov).
4.6. Deconvolution of the Microglial Transcriptome
To interrogate microglial function within the periventricular region, we performed a computational
deconvolution of the transcriptomic data [45]. We used cell-type-specific markers for activated and
inactivated microglia based on single-cell mass cytometry of the experimental allergic encephalomyelitis
mouse model [24], as shown in Table 10. These markers were used to define co-expression networks which
were constructed in GeneMANIA (http://www.genemania.org). The parameters used were as follows:
maximum resultant genes: 20; maximum resultant attributes: 10; and the co-expression category used for
gene interconnection [46]. As a final validation, co-expression networks focussed on microglial subtypes
associated with human CNS cells using an independent dataset (http://www.brainrnaseq.org/) [47].
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Table 10. Microglial gene signature: Group A (inactivated) and Group B (activated).
Gene Symbol Gene Name
Group A CD317 (BST2) Bone marrow stromal cell antigen 2
Group B
CD39 (ENTPD1) Ectonucleoside Triphosphate Diphosphohydrolase 1
HLA-DRA Major Histocompatibility Complex, Class II, DR Alpha
CD86 Cluster of differentiation 86
CD80 Cluster of differentiation 80
CD274 Cluster of differentiation 274
TIMD4 T Cell Immunoglobulin and Mucin Domain Containing 4
CD11C (ITGAX) Integrin Subunit Alpha X
TREM2 Triggering Receptor Expressed on Myeloid Cells 2
CCR5 C-C chemokine receptor type 5
MRC1 Mannose Receptor C-Type 1
4.7. Validation of Gene Expression Changes—NanoString
Validation of key changes in the gene expression profiles identified by the microarray analysis was
conducted using NanoString, an independent platform which enables the quantification of mRNA without
the use of reverse transcription or amplification of cDNA [35]. The gene expression profiles of 9 samples
(4 control and 5 PVL) were analysed using a customised CodeSet human gene panel consisting of 29
inflammation, antigen processing and presentation related genes, and 3 housekeeping genes (NanoString
Technologies, Seattle, WA, USA), as shown in Table 11. Briefly, 50 ng of RNA extracted from each LCM-ed
periventricular white matter region was added to the CodeSet in hybridisation buffer and incubated at
65 ◦C for 22 h in a thermocycler. Raw data (RCC files) were analysed using NanoString data analysis
software nSolver v4.0.70 (NanoString Technologies, Seattle, WA, USA). Data were normalized to the
geometric mean of housekeeping genes in the designed CodeSet. Both the Affymetrix and NanoString
datasets were compared to assess expression of the validation candidates.
Table 11. Nanostring validation candidates.
Function Gene Symbol Gene Name
Inflammation AKT3
V-akt murine thymoma viral oncogene homolog 3/RAC-gamma
serine/threonine-protein kinase
CCL2 C-C motif chemokine ligand 2
CCL3 C-C motif chemokine ligand 3
CCL4 C-C motif chemokine ligand 4
CCR5 C-C motif chemokine receptor 5 (gene/pseudogene)
COL6A3 Collagen type VI alpha 3 chain
CX3CR1 C-X3-C motif chemokine receptor 1
IFNAR1 Interferon alpha and beta receptor subunit 1
IKBKB Inhibitor of nuclear factor kappa B kinase subunit beta
IL1A Interleukin 1 alpha
IL1B Interleukin 1 beta
JUN Jun proto-oncogene, AP-1 transcription factor subunit
PTGS2 Prostaglandin-endoperoxide synthase 2
Antigen processing and presentation
CD74 CD74 molecule, HLA class II histocompatibility antigen gamma chain
HLA-DRA Major histocompatibility complex, class II, DR alpha
CD8A CD8a molecule, T-cell surface glycoprotein CD8 alpha chain
CD163 CD163 molecule, Scavenger Receptor Cysteine-Rich Type 1 Protein M130
CD14 Monocytes EPSTI1 Epithelial stromal interaction protein 1
FGL2 Fibrinogen like 2
FPR1 Formyl peptide receptor 1
IGSF6 Immunoglobulin superfamily member 6
PHF21A PHD finger protein 21A
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Table 11. Cont.
Function Gene Symbol Gene Name
Inactivated Microglia
IRF7 Interferon regulatory factor 7
OAS1 2’-5’-oligoadenylate synthetase 1
RSAD2 Radical S-adenosyl methionine domain containing 2
Activated Microglia FCER1G Fc fragment of IgE receptor Ig
MSR1 Macrophage scavenger receptor 1
SLAMF8 SLAM family member 8
CYBB Cytochrome b-245, beta polypeptide
Housekeeping Genes
ACTB Actin cytoplasmic 1
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
RPLP0 60S acidic ribosomal protein P0
4.8. Validation of Gene Expression Changes—Immunohistochemistry
To further validate the gene expression changes identified in the microarray analysis, expression
of the protein encoded by a panel of candidate genes was assessed by immunohistochemistry using a
standard ABC-HRP approach. The antibody details are shown in Table 9. Selected regions of interest
were marked on H&E sections and mapped onto consecutive immunostained slides. Quantification
of specific immunoreactivity was performed by capturing bright-field microscopic images within the
marked area using a Nikon Eclipse 80i microscope. The image was thresholded and the immunoreactive
area of the field determined per total area examined. Image capture and analysis was performed using
AnalysisˆD software (Nikon, Kingston Upon Thames, UK). Immunohistochemical data were not normally
distributed and did not show equality of variances between groups using the Shapiro–Wilk test; therefore,
analyses were performed using non-parametric methods. Statistical comparisons of quantitative data
between groups were carried out using the Kruskal–Wallis test using SPSS software version 26.0 (SPSS Inc.,
Chicago, IL, USA). In the case of a significant result, the p value was adjusted for multiple testing using the
Bonferroni correction method and considered significant if p < 0.05.
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Abbreviations
ABC-HRP avidin-biotin complex-horse radish peroxidase
ACTB actin cytoplasmic 1
AKT3 V-akt murine thymoma viral oncogene homolog 3
Int. J. Mol. Sci. 2020, 21, 7924 18 of 22
BBB blood brain-barrier
BST2 CD317, tethrin
CACNA1E calcium voltage-gated channel subunit alpha 1E
CALM calmodulin
CAMK2A calcium/calmodulin-dependent protein kinase II alpha
CAMK4 calcium/calmodulin-dependent protein kinase IV
cAMP cyclic adenosine monophosphateP
CCL2 C-C motif chemokine ligand 2
CCL3 C-C motif chemokine ligand 3
CCL4 C-C motif chemokine ligand 4
CCR5 C-C motif chemokine receptor 5 (gene/pseudogene)
CD163 CD163 molecule, Scavenger Receptor Cysteine-Rich Type 1 Protein M130
CD274 cluster of differentiation 274, programmed death-ligand 1
CD74 CD74 molecule, HLA class II histocompatibility antigen gamma chain
CD80 co-stimulatory molecule B7-2
CD86 cluster of differentiation 86, B7-2
CD8A CD8a molecule, T-cell surface glycoprotein CD8 alpha chain
cDNA complementary DNA
CFAS Cognitive Function and Ageing Study
CNS central nervous system
COL6A3 collagen type VI alpha 3 chain
CX3CR1 C-X3-C motif chemokine receptor 1
CYBB cytochrome b-245, beta polypeptide
DAVID Database for Annotation, Visualization and Integrated Discovery
DEPC diethylpyrocarbonate
DSCL deep subcortical lesions
ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1
EPSTI1 epithelial stromal interaction protein 1
FCER1G Fc fragment of IgE receptor Ig
FCGR1A Fc fragment of immunoglobulin gamma Fc receptor 1A
FCGR2A Fc fragment of immunoglobulin gamma Fc receptor 2A
FGL2 fibrinogen like 2
FPR1 formyl peptide receptor 1
GABA gamma-aminobutyric acid
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GBP5 guanylate-binding protein 5
GEO gene expression omnibus
GRIA glutamate receptor, ionotropic, AMPA
GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1
H&E haematoxylin and eosin
HAVCR2 hepatitis A virus cellular receptor 2
HLA-DMB major histocompatibility complex, class II, DM beta
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1
HLA-DPB1 major histocompatibility complex, class II, DP beta 1
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1
HLA-DRA major histocompatibility complex, class II, DR alpha
IFI35 interferon induced protein 35
IFI44 interferon induced protein 44
IFI44L interferon induced protein 44-like
IFIT1 interferon induced protein with tetratricopeptide repeats 1
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IFIT3 interferon induced protein with tetratricopeptide repeats 3
IFNAR1 interferon alpha receptor subunit 1
IGSF6 immunoglobulin superfamily member 6
IHC immunohistochemistry
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta
IL1A interleukin 1 alpha
IL1B interleukin 1 beta
IRF7 interferon regulatory factor 7
IRF9 interferon regulatory factor 9
ISG15 interferon-stimulated gene 15
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit), CD11c
IVT in vitro transcription
JUN jun proto-oncogene, AP-1 transcription factor subunit
KEGG Kyoto Encyclopedia of Genes and Genomes
LCM laser capture microdissection
LCP2 lymphocyte cytosolic protein 2
LFB luxol fast blue
LY6E lymphocyte antigen 6E
MAPK mitogen-activated protein kinase
MHC-II major histocompatibility complex class II
MRC1 mannose receptor C-type 1
MRI magnetic resnance imaging
mRNA messenger ribonucleic acid
MS4A6A membrane spanning 4-domains A6A
MSR1 macrophage scavenger receptor 1
MX1 MX dynamin like GTPase 1
OAS1 2’-5’-oligoadenylate synthetase 1
OAS2 2’-5’-oligoadenylate synthetase 2
OAS3 2’-5’-oligoadenylate synthetase 3
PCA principal component analysis
PHF21A PHD finger protein 21A
PI3K-Akt phosphatidylinositol 3-kinase-protein kinase
PTGS2 prostaglandin-endoperoxide synthase 2
PVL periventricular lesions
QC quality control
REC research ethics committee
RPLP0 60S acidic ribosomal protein P0
RSAD2 radical S-adenosyl methionine domain containing 2
RT room temperature
SAMSN1 SAM domain, SH3 domain and nuclear localisation signals 1
SLAMF8 SLAM family member 8
TAC transcriptome analysis console
TFEC transcription factor EC
TREM2 triggering receptor expressed on myeloid cells 2
UBE2L6 ubiquitin conjugating enzyme E2 L6
USP18 ubiquitin specific peptidase 18
WM white matter
WML white matter lesions
XAF1 XIAP-associated factor 1
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